ClinicalTrials.gg
RecruitingNCT07641075Updated Jun 11, 2026

Effects of High-Dose Vitamin D on Hormones, Neuromuscular Function, Cognition, and Body Composition in Athletes

An interventional study of Vitamin D supplementation and Placebo in Vitamin D 25-Hydroxylase Deficiency and Vitamin D Deficiency/Insufficiency, sponsored by The Jerzy Kukuczka Academy of Physical Education in Katowice. Recruiting at 1 site in Poland. Open to participants aged 17 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by The Jerzy Kukuczka Academy of Physical Education in Katowice · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jul 2025, registered May 2026).
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
17 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies testing Vitamin D in Vitamin D Deficiency — 15 open to participants now, 16 under way, none of them phase 3. Vitamin D · Vitamin D Deficiency.

Planned enrollment
17th of 153
200 · median 75
Started
2025
with 4 others
No phase
87 of 154
12 open now
Primary completion
2025-07
later than 5 of 15 live
Registered
153rd of 154
by date

Among the 154 studies testing Vitamin D in Vitamin D Deficiency, this one is the 17th largest by planned enrollment of the 153 interventional ones that give a count, is one of 5 that started in 2025, is one of 87 with no phase, reaches primary completion later than 5 of the 15 other live ones, and was the 153rd registered.

Vitamin D Deficiency

800 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

Browse Vitamin D Deficiency studies →

Open to participants now

15 of the 154 studies testing Vitamin D in Vitamin D Deficiency are open now, in 8 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About Vitamin D

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 37 Vitamin D Deficiency studies recruiting now, 16 (43%) set no upper age limit and 18 (49%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 17 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies testing Vitamin D in Vitamin D Deficiency, or all of them as a file.
02

Study summary

This study aims to evaluate the effects of high-dose vitamin D3 supplementation on selected physiological, neuromuscular, and cognitive parameters in athletes. At the baseline visit, participants will undergo a series of assessments at the Functional Research Laboratory at AWF Katowice, including a 10 mL venous blood sample collection, body composition analysis (via InBody and DEXA scans), neuromuscular function evaluation using tensiomyography (TMG), and computerized cognitive tests via the Vienna Test System.

Following baseline testing, participants will be randomly assigned to either the vitamin D3 group or the placebo group. The active group will receive a daily dose of 4,000 IU of vitamin D3 (1 capsule with dinner), while the control group will receive an identical placebo. The intervention period will last for 4 or 8 weeks. Upon completion of the supplementation period, all baseline assessments will be repeated to evaluate the post-intervention changes.

Read the detailed description

For the first visit, the participant is invited to the Functional Research Laboratory at the Academy of Physical Education (AWF) in Katowice. The visit will be initiated with a blood sample collection (10 mL) from the cubital vein, which will be followed by body mass and body composition measurements. These measurements will be performed using the InBody device (in a standing position, in light clothing or underwear) and a DEXA scan (in a supine position, in light clothing), which is utilized to evaluate bone and fat tissue using a minimal dose of X-ray radiation.

As the next stage, a tensiomyographic (TMG) assessment will be conducted in a supine position and in underwear. Single-use electrodes will be attached to the biceps brachii (long head) of both upper limbs and the gastrocnemius (lateral head) of both lower limbs. A completely non-invasive, very low-voltage and low-intensity electrical current will be emitted by an electrostimulator in order to induce muscle contraction and measure its response speed. This assessment will be performed at rest, without a warm-up, is entirely harmless, and can be repeated.

Subsequently, cognitive function tests will be performed using the computerized Vienna Test System (SCHUHFRIED GmbH, Austria). The first test involves reading color-words and naming colors, while the second test involves reading words in an incongruent color and naming colors with an incongruent meaning. Responses will be provided by pressing one of four buttons on a specialized keyboard (time limit: 2500 ms per trial). Each diagnostic block (60 trials) will be preceded by a practice block (10 trials).

Following the completion of all assessments, the participant will be randomly assigned to one of two groups: the supplemented group (vitamin D3) or the placebo group. The randomization into groups will be carried out using balls placed in a black bag. Depending on the assigned group, and once the 25(OH)D3 level results are obtained by the research team (the next business day), the supplement in an appropriate dose or a placebo product will be allocated. The collection of the products will take place on the 3rd day from the start of the project. The dose of vitamin D3 will be of 4,000 IU/day. If assignment to the placebo group occurs during randomization, a placebo supplement will be provided. The supplements will be consumed 1 capsule in the evening (with dinner). The supplementation period will last for 4 or 8 weeks.

After 4 or 8 weeks of supplementation, the study will be concluded, at which point the participant will be invited to AWF again, where all assessments from stage 1 will be repeated.

03

Conditions studied

  • Vitamin D 25-Hydroxylase Deficiency
  • Vitamin D Deficiency/Insufficiency

Browse trials for

Keywords

  • vitamin D
  • athletes
  • coggnitive function
  • neuro-muscular function
  • hormones
  • speed
  • performance
04

Who can participate

Ages eligible
17 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a minimum of 8 years of training experience,
  • absence of injuries in the 6 months leading up to the assessments,
  • consistent engagement in training sessions a minimum of 5 times per week over the last 6 months.

Exclusion criteria

Exclusion Criteria:

  • vitamin D supplementation within one month prior to the study,
  • use of multivitamin supplements,
  • intestinal disorders.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Vitamin D3 supplemented group

    Participants in this arm will receive vitamin D3 supplementation at a total daily dose of 4,000 IU. The supplement will be administered 1 capsule in the evening (with dinner). The intervention period will last for either 4 or 8 weeks.

    Dietary Supplement: Vitamin D supplementation

  • Placebo comparator
    Placebo supplementation group

    Participants in this arm will receive placebo supplementation. The supplement will be administered capsule in the evening (with dinner). The intervention period will last for either 4 or 8 weeks.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementVitamin DStudies of Vitamin DVitamin D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vitamin D3 will be administered orally in the form of capsules. Participants will ingest a total daily dose of 4,000 IU, split into two doses: 1 capsule (4,000 IU) in the evening with dinner. The intervention will be carried out daily for a duration of either 4 or 8 weeks. Supplementation compliance will be monitored by the research team through capsule counting during follow-up visits.

  • Dietary supplementPlacebo

    An identical placebo will be administered orally in the form of capsule, matching the active vitamin D3 supplement in appearance, size, color, and taste. Participants will ingest 1 placebo capsule in the evening with dinner daily for a duration of either 4 or 8 weeks.

06

What researchers measure

Primary outcomes

  1. Serum 25-Hydroxyvitamin D Concentration

    Description: Serum concentration of 25-hydroxyvitamin D \[25(OH)D\] measured using a validated laboratory method to assess vitamin D status. Unit of Measure: ng/mL

    Time frame: 8-weeks

Secondary outcomes

  1. Corsi Block-Tapping Test - Block Time

    Description: Visuospatial working memory assessed using the Corsi Block-Tapping Test. Block Time represents the reaction time required to complete the task. Unit of Measure: ms

    Time frame: 8-weeks

  2. Corsi Block-Tapping Test - Reverse Span Score

    Description: Visuospatial working memory performance assessed using the reverse recall condition of the Corsi Block-Tapping Test. Unit of Measure: score

    Time frame: 8-weeks

  3. Corsi Block-Tapping Test - Unweighted Block Span

    Description: Maximum sequence length correctly reproduced during the Corsi Block-Tapping Test. Unit of Measure: blocks

    Time frame: 8-weeks

Other outcomes

  1. Countermovement Jump Height

    Description: Lower-body explosive power assessed using the Countermovement Jump (CMJ) test. Unit of Measure: cm

    Time frame: 8-weeks

  2. Sprint Performance

    Description: Sprint performance assessed during a short-distance sprint test. Unit of Measure:s

    Time frame: 8-weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: Start data- 20.05.2026 End- 31.12.2028

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jul 2025, 0 months.

Of 167 non-industry interventional studies with no phase under Vitamin D Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's 0 months is below that.

Counting every sponsor, half of 169 studies reached it within 11 months; a quarter within 4 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 11, 2026
StartActual
Jul 1, 2025
Primary completionActual
Jul 10, 2025
CompletionEst.
Dec 31, 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07641075
Lead sponsor
The Jerzy Kukuczka Academy of Physical Education in Katowice
Responsible party
Małgorzata Magdalena Michalczyk (assistant profesor, The Jerzy Kukuczka Academy of Physical Education in Katowice) — Principal investigator
First posted
Jun 11, 2026
Start date
Jul 1, 2025
Primary completion
Jul 10, 2025
Completion
Dec 31, 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Małgorzata Michalczyk, Profesor
Contact
m.michalczyk@awf.katowice.pl
+48535016532
Małgorzata Michalczyk, Profesor
Contact
m.michalczyk@awf.katowice.pl
535016532

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin D

Start the discussion